Levocetirizine DihydrochlorideThird Party Manufacturing in India

Levocetirizine Dihydrochloride is the pharmacologically active R-enantiomer of cetirizine, a second-generation antihistamine that works by selectively and potently blocking peripheral histamine H1 receptors. By occupying these receptor sites, levocetirizine prevents histamine from binding and triggering the cascade of allergic inflammatory responses. This action effectively inhibits histamine-mediated effects such as vasodilation, increased vascular permeability, bronchoconstriction, and sensory nerve stimulation that cause itching and sneezing. Unlike first-generation antihistamines, levocetirizine has a much lower affinity for central nervous system H1 receptors due to its reduced lipophilicity, resulting in significantly less sedation and cognitive impairment. It also demonstrates some anti-inflammatory properties by inhibiting the release of pro-inflammatory cytokines and mediators from mast cells, basophils, and eosinophils. The drug achieves peak plasma concentration within approximately one hour of oral administration and has a duration of action lasting up to 24 hours, enabling convenient once-daily dosing. Levocetirizine is minimally metabolized in the liver and is primarily excreted unchanged in the urine, making its pharmacokinetic profile predictable and consistent. This targeted peripheral H1 receptor blockade provides rapid, sustained relief from allergic symptoms without the drowsiness commonly associated with older antihistamine therapies.

Therapeutic Uses

Levocetirizine Dihydrochloride is prescribed for the management of:

• Seasonal and Perennial Allergic Rhinitis: Provides effective relief from nasal congestion, sneezing, rhinorrhea, nasal itching, and postnasal drip associated with environmental allergens including pollens, dust mites, and mold spores.
• Chronic Idiopathic Urticaria: Reduces the frequency, severity, and duration of hives, wheals, and associated pruritus in patients with chronic spontaneous urticaria of unknown origin.
• Allergic Dermatological Conditions: Offers symptom control for histamine-mediated skin conditions presenting with itching, erythema, and localized swelling.
• Pediatric Allergic Conditions: Approved for use in children aged six months and older, providing a safe and well-tolerated option for managing pediatric allergic rhinitis and urticaria.

Why Manufacturers Choose Levocetirizine Dihydrochloride

Levocetirizine Dihydrochloride is one of the most widely prescribed second-generation antihistamines globally, occupying a dominant position in the allergy therapeutic category. Its once-daily dosing regimen, rapid onset of action, and superior safety profile compared to older antihistamines make it a consistent high-volume product across both prescription and over-the-counter markets. For pharmaceutical manufacturers, levocetirizine offers excellent profit margins and stable year-round demand that peaks predictably during seasonal allergy periods. Its established position in international clinical guidelines ensures continuous procurement by government health systems and hospital formularies. Sourcing levocetirizine from a WHO-GMP certified third party manufacturer in India guarantees compliance with the highest international quality standards while benefiting from India's cost-efficient active pharmaceutical ingredient supply chain and manufacturing infrastructure.

This makes Levocetirizine Dihydrochloride one of the most sought-after products for third party manufacturing and PCD pharma franchise in India, with strong demand from both domestic and export markets across Asia, Africa, and Latin America.